| scholarly article | Q13442814 |
| P50 | author | Frank Maldarelli | Q90433858 |
| Jason M Brenchley | Q114512804 | ||
| Kuan-Teh Jeang | Q18235906 | ||
| P2093 | author name string | Venkat S R K Yedavalli | |
| Klaus Strebel | |||
| Paul Liu | |||
| Molly Perkins | |||
| Laurent Houzet | |||
| Zachary Klase | |||
| P2860 | cites work | BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources | Q21183895 |
| T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction | Q24300389 | ||
| Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid | Q24596282 | ||
| Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells | Q24644201 | ||
| Tat gets the "green" light on transcription initiation | Q24815711 | ||
| Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein | Q27860488 | ||
| WebLogo: A Sequence Logo Generator | Q27860646 | ||
| The RUNX genes: gain or loss of function in cancer | Q28247901 | ||
| Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist | Q28325213 | ||
| The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter | Q28368856 | ||
| PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis | Q32884406 | ||
| The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates | Q33781796 | ||
| Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells | Q33787937 | ||
| Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. | Q34161703 | ||
| Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection | Q34242229 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction | Q34388355 | ||
| The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit | Q34544409 | ||
| Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy | Q34714816 | ||
| HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. | Q34985945 | ||
| RUNX transcription factor-mediated association of Cd4 and Cd8 enables coordinate gene regulation | Q35005536 | ||
| Structure and regulated expression of mammalian RUNX genes | Q35779684 | ||
| Role of RUNX family members in transcriptional repression and gene silencing | Q35779689 | ||
| Epigenetic gene silencing by Runx proteins | Q35779768 | ||
| HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition | Q35874198 | ||
| Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation | Q36329898 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. | Q36832567 | ||
| Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription | Q36870972 | ||
| RUNX proteins in transcription factor networks that regulate T-cell lineage choice | Q37376016 | ||
| Runx and ThPOK: a balancing act to regulate thymocyte lineage commitment | Q37500268 | ||
| Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns | Q37596450 | ||
| Mechanisms of HIV latency: an emerging picture of complexity | Q37738147 | ||
| Regulation of gene expression in peripheral T cells by Runx transcription factors | Q37748069 | ||
| Interplay of transcription factors in T-cell differentiation and function: the role of Runx | Q37811064 | ||
| Epigenetic regulation of HIV latency | Q37829626 | ||
| HDAC inhibitors in HIV. | Q37956178 | ||
| Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma | Q39262129 | ||
| TEThered to Runx: novel binding partners for runx factors | Q39719445 | ||
| Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera | Q40568990 | ||
| A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team | Q42276768 | ||
| HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. | Q42348425 | ||
| Down-regulation of Runx1 expression by TCR signal involves an autoregulatory mechanism and contributes to IL-2 production. | Q42703663 | ||
| Over-expression of Runx1 transcription factor impairs the development of thymocytes from the double-negative to double-positive stages. | Q43183907 | ||
| CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. | Q43239447 | ||
| Using TESS to predict transcription factor binding sites in DNA sequence | Q44375395 | ||
| Tat trans-activates the human immunodeficiency virus through a nascent RNA target | Q45847022 | ||
| Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. | Q52111650 | ||
| Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. | Q54631830 | ||
| HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429 | Q72182513 | ||
| Functional redundancy of transcription factor-binding sites in the killer cell Ig-like receptor (KIR) gene promoter | Q79833910 | ||
| Perspectives on RUNX genes: an update | Q84730573 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ro-5-3335 | Q27887134 |
| P304 | page(s) | e1003997 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA | |
| P478 | volume | 10 |
| Q89682052 | Benzodiazepines Drive Alteration of Chromatin at the Integrated HIV-1 LTR |
| Q39181425 | CBFß and HIV Infection. |
| Q37714020 | CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G. |
| Q59359728 | CD4 T Cell Subsets and Pathways to HIV Latency |
| Q36250079 | CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs |
| Q93062057 | Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells |
| Q92945663 | Deep latency: A new insight into a functional HIV cure |
| Q90440611 | Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells |
| Q37391971 | Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals |
| Q37348748 | Gene-expression reversal of lncRNAs and associated mRNAs expression in active vs latent HIV infection |
| Q49851068 | HIV latency is reversed by ACSS2-driven histone crotonylation |
| Q36364264 | Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach |
| Q40725476 | Lentivirus pre-packed with Cas9 protein for safer gene editing |
| Q36185332 | Lineage-Specific Viral Hijacking of Non-canonical E3 Ubiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 Activity |
| Q92349060 | Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations |
| Q52680804 | Long Noncoding RNA uc002yug.2 Activates HIV-1 Latency through Regulation of mRNA Levels of Various RUNX1 Isoforms and Increased Tat Expression. |
| Q41927990 | Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription |
| Q26795463 | Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 |
| Q52816327 | Novel Latency Reversal Agents for HIV-1 Cure. |
| Q40108650 | Real-time visualization of chromatin modification in isolated nuclei. |
| Q40398221 | Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection |
| Q37662400 | Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia |
| Q37113972 | The role of Fc receptors in HIV prevention and therapy |
| Q39160623 | Underlying mechanisms of HIV-1 latency. |
Search more.